Skip to main content
Erschienen in: Journal of Cancer Education 4/2015

01.12.2015

Comprehension of Randomization and Uncertainty in Cancer Clinical Trials Decision Making Among Rural, Appalachian Patients

verfasst von: Janice L. Krieger, Angela Palmer-Wackerly, Phokeng M. Dailey, Jessica L. Krok-Schoen, Nancy E. Schoenberg, Electra D. Paskett

Erschienen in: Journal of Cancer Education | Ausgabe 4/2015

Einloggen, um Zugang zu erhalten

Abstract

Comprehension of randomization is a vital, but understudied, component of informed consent to participate in cancer randomized clinical trials (RCTs). This study examines patient comprehension of the randomization process as well as sources of ongoing uncertainty that may inhibit a patient’s ability to provide informed consent to participate in RCTs. Cancer patients living in rural Appalachia who were offered an opportunity to participate in a cancer treatment RCT completed in-depth interviews and a brief survey. No systematic differences in randomization comprehension between patients who consented and those who declined participation in a cancer RCT were detected. Comprehension is conceptually distinct from uncertainty, with patients who had both high and low comprehension experiencing randomization-related uncertainty. Uncertainty about randomization was found to have cognitive and affective dimensions. Not all patients enrolling in RCTs have a sufficient understanding of the randomization process to provide informed consent. Healthcare providers need to be aware of the different types of randomization-related uncertainty. Efforts to improve informed consent to participate in RCTs should focus on having patients teach back their understanding of randomization. This practice could yield valuable information about the patient’s cognitive and affective understanding of randomization as well as opportunities to correct misperceptions. Education about RCTs should reflect patient expectations of individualized care by explaining how all treatments being compared are appropriate to the specifics of a patient’s disease.
Literatur
1.
Zurück zum Zitat Brown R, Butow P, Ellis P, Boyle F, Tattersall MH (2004) Seeking informed consent to cancer clinical trials: describing current practice. Soc Sci Med 58(12):2445–2457CrossRefPubMed Brown R, Butow P, Ellis P, Boyle F, Tattersall MH (2004) Seeking informed consent to cancer clinical trials: describing current practice. Soc Sci Med 58(12):2445–2457CrossRefPubMed
2.
Zurück zum Zitat Sinha G (2007) United Kingdom becomes the cancer clinical trials recruitment capital of the world. J Natl Cancer Inst 99(6):420–422CrossRefPubMed Sinha G (2007) United Kingdom becomes the cancer clinical trials recruitment capital of the world. J Natl Cancer Inst 99(6):420–422CrossRefPubMed
3.
Zurück zum Zitat Joffe S, Cook EF, Cleary PD, Clark JW, Weeks JC (2001) Quality of informed consent in cancer clinical trials: a cross-sectional survey. Lancet 358(9295):1772–1777CrossRefPubMed Joffe S, Cook EF, Cleary PD, Clark JW, Weeks JC (2001) Quality of informed consent in cancer clinical trials: a cross-sectional survey. Lancet 358(9295):1772–1777CrossRefPubMed
4.
Zurück zum Zitat Chapman K, Abraham C, Jenkins V, Fallowfield L (2003) Lay understanding of terms used in cancer consultations. Psycho-Oncology 12(6):557–566CrossRefPubMed Chapman K, Abraham C, Jenkins V, Fallowfield L (2003) Lay understanding of terms used in cancer consultations. Psycho-Oncology 12(6):557–566CrossRefPubMed
5.
Zurück zum Zitat Barnett MM (2006) Does it hurt to know the worst?—psychological morbidity, information preferences and understanding of prognosis in patients with advanced cancer. Psycho-Oncology 15(1):44–55CrossRefPubMed Barnett MM (2006) Does it hurt to know the worst?—psychological morbidity, information preferences and understanding of prognosis in patients with advanced cancer. Psycho-Oncology 15(1):44–55CrossRefPubMed
6.
Zurück zum Zitat Tang ST, Lee S-YC (2004) Cancer diagnosis and prognosis in Taiwan: patient preferences versus experiences. Psycho-Oncology 13(1):1–13CrossRefPubMed Tang ST, Lee S-YC (2004) Cancer diagnosis and prognosis in Taiwan: patient preferences versus experiences. Psycho-Oncology 13(1):1–13CrossRefPubMed
7.
Zurück zum Zitat Kerr C, Robinson E, Stevens A, Braunholtz D, Edwards S, Lilford R (2004) Randomisation in trials: do potential trial participants understand it and find it acceptable? J Med Ethics 30(1):80–84PubMedCentralCrossRefPubMed Kerr C, Robinson E, Stevens A, Braunholtz D, Edwards S, Lilford R (2004) Randomisation in trials: do potential trial participants understand it and find it acceptable? J Med Ethics 30(1):80–84PubMedCentralCrossRefPubMed
8.
Zurück zum Zitat Krieger JL (2014) Last resort or roll of the die? Exploring the role of metaphors in cancer clinical trials education among medically underserved populations. J Health Commun 19(10):1161–77 Krieger JL (2014) Last resort or roll of the die? Exploring the role of metaphors in cancer clinical trials education among medically underserved populations. J Health Commun 19(10):1161–77
9.
Zurück zum Zitat Krieger JL, Parrott RL, Nussbaum JF (2011) Metaphor use and health literacy: a pilot study of strategies to explain randomization in cancer clinical trials. J Health Commun 16(1):3–16CrossRefPubMed Krieger JL, Parrott RL, Nussbaum JF (2011) Metaphor use and health literacy: a pilot study of strategies to explain randomization in cancer clinical trials. J Health Commun 16(1):3–16CrossRefPubMed
10.
Zurück zum Zitat Featherstone K, Donovan JL (1998) Random allocation or allocation at random? Patients’ perspectives of participation in a randomised controlled trial. BMJ 317(7167):1177–1180PubMedCentralCrossRefPubMed Featherstone K, Donovan JL (1998) Random allocation or allocation at random? Patients’ perspectives of participation in a randomised controlled trial. BMJ 317(7167):1177–1180PubMedCentralCrossRefPubMed
11.
Zurück zum Zitat Mishel MH (1988) Uncertainty in illness. J Nurs Scholarsh 20(4):225–232CrossRef Mishel MH (1988) Uncertainty in illness. J Nurs Scholarsh 20(4):225–232CrossRef
12.
Zurück zum Zitat Babrow AS, Kasch CR, Ford LA (1998) The many meanings of uncertainty in illness: toward a systematic accounting. Health Commun 10(1):1–23CrossRefPubMed Babrow AS, Kasch CR, Ford LA (1998) The many meanings of uncertainty in illness: toward a systematic accounting. Health Commun 10(1):1–23CrossRefPubMed
13.
Zurück zum Zitat Brashers DE (2001) Communication and uncertainty management. J Commun 51(3):477–497CrossRef Brashers DE (2001) Communication and uncertainty management. J Commun 51(3):477–497CrossRef
14.
Zurück zum Zitat Brashers DE, Neidig JL, Russell JA, Cardillo LW, Haas SM, Dobbs LK et al (2003) The medical, personal, and social causes of uncertainty in HIV illness. Issues Ment Health Nurs 24(5):497–522CrossRefPubMed Brashers DE, Neidig JL, Russell JA, Cardillo LW, Haas SM, Dobbs LK et al (2003) The medical, personal, and social causes of uncertainty in HIV illness. Issues Ment Health Nurs 24(5):497–522CrossRefPubMed
15.
Zurück zum Zitat Curbow B, Fogarty LA, McDonnell K, Chill J, Scott LB (2004) Can a brief video intervention improve breast cancer clinical trial knowledge and beliefs? Soc Sci Med 58(1):193–205CrossRefPubMed Curbow B, Fogarty LA, McDonnell K, Chill J, Scott LB (2004) Can a brief video intervention improve breast cancer clinical trial knowledge and beliefs? Soc Sci Med 58(1):193–205CrossRefPubMed
16.
Zurück zum Zitat Pitts MJ, Fowler C, Kaplan MS, Nussbaum J, Becker C (2009) Dialectical tensions underpinning family farm succession planning. J Appl Commun Res 37(1):59–79CrossRef Pitts MJ, Fowler C, Kaplan MS, Nussbaum J, Becker C (2009) Dialectical tensions underpinning family farm succession planning. J Appl Commun Res 37(1):59–79CrossRef
17.
Zurück zum Zitat Charmaz K (2006) Constructing grounded theory: a practical guide through qualitative analysis. Sage Publications, Los Angeles Charmaz K (2006) Constructing grounded theory: a practical guide through qualitative analysis. Sage Publications, Los Angeles
18.
Zurück zum Zitat Patton MQ (2002) Qualitative research and evaluation methods. Sage Publications, Thousand Oaks, CA Patton MQ (2002) Qualitative research and evaluation methods. Sage Publications, Thousand Oaks, CA
19.
Zurück zum Zitat Lincoln YS, Guba EG (1985) Naturalistic inquiry. Sage Publications, Beverly Hills Lincoln YS, Guba EG (1985) Naturalistic inquiry. Sage Publications, Beverly Hills
20.
Zurück zum Zitat Blackley D, Behringer B, Zheng S (2012) Cancer mortality rates in Appalachia: descriptive epidemiology and an approach to explaining differences in outcomes. J Community Health 37(4):804–813CrossRefPubMed Blackley D, Behringer B, Zheng S (2012) Cancer mortality rates in Appalachia: descriptive epidemiology and an approach to explaining differences in outcomes. J Community Health 37(4):804–813CrossRefPubMed
Metadaten
Titel
Comprehension of Randomization and Uncertainty in Cancer Clinical Trials Decision Making Among Rural, Appalachian Patients
verfasst von
Janice L. Krieger
Angela Palmer-Wackerly
Phokeng M. Dailey
Jessica L. Krok-Schoen
Nancy E. Schoenberg
Electra D. Paskett
Publikationsdatum
01.12.2015
Verlag
Springer US
Erschienen in
Journal of Cancer Education / Ausgabe 4/2015
Print ISSN: 0885-8195
Elektronische ISSN: 1543-0154
DOI
https://doi.org/10.1007/s13187-015-0789-0

Weitere Artikel der Ausgabe 4/2015

Journal of Cancer Education 4/2015 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.